RemeGen Co., Ltd. (“RemeGen” or “the Company”) (HKG: 9995, SHA: 688331), a commercial-stage biotechnology company, is invited …
Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis
Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases …
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
Today, Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- …
ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement
ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with AlgenScribe SAS …
Turn Biotechnologies Co-Founder to Present at Prestigious ARDD Meeting in Copenhagen
Turn Biotechnologies co-founder Vittorio Sebastiano will share company data during a presentation on the potential …
